Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Metabolomic and Proteomic Techniques for Establishing Biomarkers and Improving Our Understanding of Pathophysiology in Diabetic Nephropathy.

Siwy J, Ahonen L, Magalhães P, Frantzi M, Rossing P.

Methods Mol Biol. 2020;2067:287-306. doi: 10.1007/978-1-4939-9841-8_18.

PMID:
31701458
2.

Author Correction: Urinary CE-MS peptide marker pattern for detection of solid tumors.

Belczacka I, Latosinska A, Siwy J, Metzger J, Merseburger AS, Mischak H, Vlahou A, Frantzi M, Jankowski V.

Sci Rep. 2019 Sep 3;9(1):12864. doi: 10.1038/s41598-019-49304-9.

3.

Proteome-based classification of Nonmuscle Invasive Bladder Cancer.

Stroggilos R, Mokou M, Latosinska A, Makridakis M, Lygirou V, Mavrogeorgis E, Drekolias D, Frantzi M, Mullen W, Fragkoulis C, Stasinopoulos K, Papadopoulos G, Stathouros G, Lazaris AC, Makrythanasis P, Ntoumas K, Mischak H, Zoidakis J, Vlahou A.

Int J Cancer. 2020 Jan 1;146(1):281-294. doi: 10.1002/ijc.32556. Epub 2019 Jul 26.

PMID:
31286493
4.

Urinary peptide panel for prognostic assessment of bladder cancer relapse.

Krochmal M, van Kessel KEM, Zwarthoff EC, Belczacka I, Pejchinovski M, Vlahou A, Mischak H, Frantzi M.

Sci Rep. 2019 May 21;9(1):7635. doi: 10.1038/s41598-019-44129-y.

5.

CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer.

Frantzi M, Gomez Gomez E, Blanca Pedregosa A, Valero Rosa J, Latosinska A, Culig Z, Merseburger AS, Luque RM, Requena Tapia MJ, Mischak H, Carrasco Valiente J.

Br J Cancer. 2019 Jun;120(12):1120-1128. doi: 10.1038/s41416-019-0472-z. Epub 2019 May 16.

PMID:
31092909
6.

Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: The past, the present, and the future.

Latosinska A, Siwy J, Mischak H, Frantzi M.

Electrophoresis. 2019 Sep;40(18-19):2294-2308. doi: 10.1002/elps.201900091. Epub 2019 May 14. Review.

PMID:
31054149
7.

Clinical Proteomics on the Path Toward Implementation: First Promises Delivered.

Frantzi M, Mischak H, Latosinska A.

Proteomics Clin Appl. 2019 Mar;13(2):e1800094. doi: 10.1002/prca.201800094. No abstract available.

PMID:
30767399
8.

Proteomics in Drug Development: The Dawn of a New Era?

Frantzi M, Latosinska A, Mischak H.

Proteomics Clin Appl. 2019 Mar;13(2):e1800087. doi: 10.1002/prca.201800087. Epub 2019 Feb 25. Review.

PMID:
30724014
9.

Urinary proteomic biomarkers in oncology: ready for implementation?

Frantzi M, Latosinska A, Belczacka I, Mischak H.

Expert Rev Proteomics. 2019 Jan;16(1):49-63. doi: 10.1080/14789450.2018.1547193. Epub 2018 Nov 15.

PMID:
30412678
10.

Urinary Glycopeptide Analysis for the Investigation of Novel Biomarkers.

Belczacka I, Pejchinovski M, Krochmal M, Magalhães P, Frantzi M, Mullen W, Vlahou A, Mischak H, Jankowski V.

Proteomics Clin Appl. 2019 May;13(3):e1800111. doi: 10.1002/prca.201800111. Epub 2018 Oct 18.

PMID:
30334612
11.

Promise and Implementation of Proteomic Prostate Cancer Biomarkers.

Latosinska A, Frantzi M, Merseburger AS, Mischak H.

Diagnostics (Basel). 2018 Aug 29;8(3). pii: E57. doi: 10.3390/diagnostics8030057. Review.

12.

Proteomics biomarkers for solid tumors: Current status and future prospects.

Belczacka I, Latosinska A, Metzger J, Marx D, Vlahou A, Mischak H, Frantzi M.

Mass Spectrom Rev. 2019 Jan;38(1):49-78. doi: 10.1002/mas.21572. Epub 2018 Jun 11.

PMID:
29889308
13.

Clinical Proteomics: Closing the Gap from Discovery to Implementation.

Frantzi M, Latosinska A, Kontostathi G, Mischak H.

Proteomics. 2018 Jul;18(14):e1700463. doi: 10.1002/pmic.201700463. Epub 2018 Jul 8.

PMID:
29785737
14.

Urinary CE-MS peptide marker pattern for detection of solid tumors.

Belczacka I, Latosinska A, Siwy J, Metzger J, Merseburger AS, Mischak H, Vlahou A, Frantzi M, Jankowski V.

Sci Rep. 2018 Mar 27;8(1):5227. doi: 10.1038/s41598-018-23585-y. Erratum in: Sci Rep. 2019 Sep 3;9(1):12864.

15.

Proteomics and Metabolomics for AKI Diagnosis.

Marx D, Metzger J, Pejchinovski M, Gil RB, Frantzi M, Latosinska A, Belczacka I, Heinzmann SS, Husi H, Zoidakis J, Klingele M, Herget-Rosenthal S.

Semin Nephrol. 2018 Jan;38(1):63-87. doi: 10.1016/j.semnephrol.2017.09.007. Review.

PMID:
29291763
16.

Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.

Latosinska A, Mokou M, Makridakis M, Mullen W, Zoidakis J, Lygirou V, Frantzi M, Katafigiotis I, Stravodimos K, Hupe MC, Dobrzynski M, Kolch W, Merseburger AS, Mischak H, Roubelakis MG, Vlahou A.

Oncotarget. 2017 Apr 20;8(41):69435-69455. doi: 10.18632/oncotarget.17279. eCollection 2017 Sep 19.

17.

Clinical Proteomics for Precision Medicine: The Bladder Cancer Case.

Latosinska A, Frantzi M, Vlahou A, Merseburger AS, Mischak H.

Proteomics Clin Appl. 2018 Mar;12(2). doi: 10.1002/prca.201700074. Epub 2017 Oct 25. Review.

PMID:
28980455
18.

Ten Years of Proteomics in Bladder Cancer: Progress and Future Directions.

Frantzi M, Vlahou A.

Bladder Cancer. 2017 Jan 27;3(1):1-18. doi: 10.3233/BLC-160073. Review.

19.

Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca2+ signaling in T24M-based bladder cancer models.

Frantzi M, Klimou Z, Makridakis M, Zoidakis J, Latosinska A, Borràs DM, Janssen B, Giannopoulou I, Lygirou V, Lazaris AC, Anagnou NP, Mischak H, Roubelakis MG, Vlahou A.

Oncotarget. 2016 Oct 25;7(43):70750-70768. doi: 10.18632/oncotarget.12218.

20.

Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of -omics findings.

Latosinska A, Makridakis M, Frantzi M, Borràs DM, Janssen B, Mullen W, Zoidakis J, Merseburger AS, Jankowski V, Mischak H, Vlahou A.

Sci Rep. 2016 May 11;6:25619. doi: 10.1038/srep25619.

21.

Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study.

Frantzi M, van Kessel KE, Zwarthoff EC, Marquez M, Rava M, Malats N, Merseburger AS, Katafigiotis I, Stravodimos K, Mullen W, Zoidakis J, Makridakis M, Pejchinovski M, Critselis E, Lichtinghagen R, Brand K, Dakna M, Roubelakis MG, Theodorescu D, Vlahou A, Mischak H, Anagnou NP.

Clin Cancer Res. 2016 Aug 15;22(16):4077-86. doi: 10.1158/1078-0432.CCR-15-2715. Epub 2016 Mar 29.

22.

Recent progress in urinary proteome analysis for prostate cancer diagnosis and management.

Frantzi M, Latosinska A, Merseburger AS, Mischak H.

Expert Rev Mol Diagn. 2015;15(12):1539-54. doi: 10.1586/14737159.2015.1104248. Epub 2015 Oct 22. Review.

PMID:
26491818
23.

Developing proteomic biomarkers for bladder cancer: towards clinical application.

Frantzi M, Latosinska A, Flühe L, Hupe MC, Critselis E, Kramer MW, Merseburger AS, Mischak H, Vlahou A.

Nat Rev Urol. 2015 Jun;12(6):317-30. doi: 10.1038/nrurol.2015.100. Epub 2015 May 26. Review.

PMID:
26032553
24.

Targeting the proteome of cellular fractions: focus on secreted proteins.

Latosinska A, Frantzi M, Mullen W, Vlahou A, Makridakis M.

Methods Mol Biol. 2015;1243:29-41. doi: 10.1007/978-1-4939-1872-0_2.

PMID:
25384738
25.

Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development.

Frantzi M, Bhat A, Latosinska A.

Clin Transl Med. 2014 Mar 29;3(1):7. doi: 10.1186/2001-1326-3-7.

26.

Discovery and validation of urinary biomarkers for detection of renal cell carcinoma.

Frantzi M, Metzger J, Banks RE, Husi H, Klein J, Dakna M, Mullen W, Cartledge JJ, Schanstra JP, Brand K, Kuczyk MA, Mischak H, Vlahou A, Theodorescu D, Merseburger AS.

J Proteomics. 2014 Feb 26;98:44-58. doi: 10.1016/j.jprot.2013.12.010. Epub 2013 Dec 25.

PMID:
24374379
27.

Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer.

Latosinska A, Frantzi M, Vlahou A, Mischak H.

Proteomics Clin Appl. 2013 Dec;7(11-12):779-93. doi: 10.1002/prca.201300038. Review.

PMID:
23970371
28.

IMAC fractionation in combination with LC-MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers.

Frantzi M, Zoidakis J, Papadopoulos T, Zürbig P, Katafigiotis I, Stravodimos K, Lazaris A, Giannopoulou I, Ploumidis A, Mischak H, Mullen W, Vlahou A.

J Proteome Res. 2013 Sep 6;12(9):3969-79. doi: 10.1021/pr400255h. Epub 2013 Aug 21.

PMID:
23924207
29.

Biomarkers for bladder cancer aggressiveness.

Frantzi M, Makridakis M, Vlahou A.

Curr Opin Urol. 2012 Sep;22(5):390-6. doi: 10.1097/MOU.0b013e328356ad0e. Review.

PMID:
22825458
30.

Proteomics approaches in the quest of kidney disease biomarkers.

Frantzi M, Bitsika V, Charonis A, Vlahou A.

Prilozi. 2011;32(2):33-51. Review.

PMID:
22286613
31.

Profilin 1 is a potential biomarker for bladder cancer aggressiveness.

Zoidakis J, Makridakis M, Zerefos PG, Bitsika V, Esteban S, Frantzi M, Stravodimos K, Anagnou NP, Roubelakis MG, Sanchez-Carbayo M, Vlahou A.

Mol Cell Proteomics. 2012 Apr;11(4):M111.009449. doi: 10.1074/mcp.M111.009449. Epub 2011 Dec 8.

Supplemental Content

Loading ...
Support Center